Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMS2IC9)

Drug Name
BMS-587101 Drug Info
Synonyms BMS-688521
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
11635371
CAS Number
CAS 509083-77-6
TTD Drug ID
DMS2IC9

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-L (ITGAL) TT48WR6 ITAL_HUMAN Inhibitor [2]
Integrin beta-2 (ITGB2) TTIJWR7 ITB2_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Integrin alpha-L (ITGAL) DTT ITGAL 3.459 4.858 3.406 3.365
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-L (ITGAL) DTT ITGAL 1.20E-33 0.79 2.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
2 Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-(... J Med Chem. 2010 May 13;53(9):3814-30.
3 Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thioph... J Med Chem. 2006 Nov 30;49(24):6946-9.